A direct healthcare cost analysis of the cryopreserved versus fresh transfer policy at the blastocyst stage

详细信息    查看全文

• 作者：Enrico Papaleo^aAuthor Vitae ; Luca Pagliardini^b ; Valeria Stella Vanni^a ; Diana Delprato^a ; Patrizia Rubino^b ; Massimo Candiani^a ; ^c ; Paola Viganò ; ^b ; ^{vigano.paola@hsr.it}
• 关键词：Blastocyst ; Cost analysis ; Freeze-all ; IVF
• 刊名：Reproductive BioMedicine Online
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：34
• 期：1
• 页码：19-26
• 全文大小：664 K
• 卷排序：34

文摘

A cost analysis covering direct healthcare costs relating to IVF freeze-all policy was conducted. Normal- and high- responder patients treated with a freeze-all policy (n = 63) compared with fresh transfer IVF (n = 189) matched by age, body mass index, duration and cause of infertility, predictive factors for IVF (number of oocytes used for fertilization) and study period, according to a 1:3 ratio were included. Total costs per patient (€6952 versus €6863) and mean costs per live birth were similar between the freeze-all strategy (€13,101, 95% CI 10,686 to 17,041) and fresh transfer IVF (€15,279, 95% CI 13,212 to 18,030). A mean per live birth cost-saving of €2178 (95% CI −1810 to 6165) resulted in a freeze-all strategy owing to fewer embryo transfer procedures (1.29 ± 0.5 versus 1.41 ± 0.7); differences were not significant. Sensitivity analysis revealed that the freeze-all strategy remained cost-effective until the live birth rate is either higher or only slightly lower (≥–0.59%) in the freeze-all group compared with fresh cycles. A freeze-all policy does not increase costs compared with fresh transfer, owing to negligible additional expenses, i.e. vitrification, endometrial priming and monitoring, against fewer embryo transfer procedures required to achieve pregnancy.